Polycystic Liver Disease — Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
Citation(s)
An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders